PBC Data From AASLD: Part 1
Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD

Released: December 06, 2023

Marlyn J Mayo
Marlyn J Mayo, MD

Activity

Progress
1
Course Completed

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including:

  • A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)
  • A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCA
  • A retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBC